REDHILL BIOPHARMA LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.428 USD | +2.82% |
|
-5.31% | -70.68% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 157.4 | 214.1 | 302.3 | 135.2 | 12.8 | 28.72 |
| Enterprise Value (EV) 1 | 104.3 | 170 | 359.4 | 185 | 115.5 | 24.33 |
| P/E ratio | -3.26 x | -4.26 x | -3.86 x | -1.23 x | -0.12 x | 0.4 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 18.8 x | 34 x | 4.7 x | 1.58 x | 0.21 x | 4.4 x |
| EV / Revenue | 12.5 x | 27 x | 5.58 x | 2.16 x | 1.87 x | 3.73 x |
| EV / EBITDA | -2.66 x | -3.97 x | -6.47 x | -2.85 x | -3.16 x | -1.1 x |
| EV / FCF | -4.85 x | -6.66 x | -5.77 x | -4.83 x | -2.2 x | -1.33 x |
| FCF Yield | -20.6% | -15% | -17.3% | -20.7% | -45.4% | -74.9% |
| Price to Book | 3.08 x | 3.57 x | 22.4 x | 15.3 x | -0.27 x | 13.9 x |
| Nbr of stocks (in thousands) | 709 | 882 | 935 | 1,310 | 2,280 | 19,675 |
| Reference price 2 | 222.0 | 242.8 | 323.2 | 103.2 | 5.612 | 1.460 |
| Announcement Date | 2/26/19 | 3/4/20 | 3/18/21 | 3/17/22 | 4/28/23 | 4/8/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 8.36 | 6.291 | 64.36 | 85.76 | 61.8 | 6.53 |
| EBITDA 1 | -39.24 | -42.88 | -55.51 | -64.88 | -36.56 | -22.15 |
| EBIT 1 | -39.33 | -43.2 | -62.88 | -72.24 | -42.84 | -22.87 |
| Operating Margin | -470.47% | -686.71% | -97.71% | -84.23% | -69.33% | -350.2% |
| Earnings before Tax (EBT) 1 | -38.82 | -42.3 | -76.17 | -97.74 | -71.67 | 23.92 |
| Net income 1 | -38.82 | -42.3 | -76.17 | -97.74 | -71.67 | 23.92 |
| Net margin | -464.35% | -672.45% | -118.36% | -113.98% | -115.97% | 366.25% |
| EPS 2 | -68.00 | -56.99 | -83.64 | -84.03 | -46.29 | 3.692 |
| Free Cash Flow 1 | -21.48 | -25.55 | -62.33 | -38.27 | -52.39 | -18.23 |
| FCF margin | -256.93% | -406.06% | -96.84% | -44.63% | -84.78% | -279.2% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 2/26/19 | 3/4/20 | 3/18/21 | 3/17/22 | 4/28/23 | 4/8/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 |
|---|---|---|---|---|---|---|
| Net sales 1 | 21.61 | 22.07 | 18.24 | 18.35 | 17.55 | 12.8 |
| EBITDA | -14.7 | -18.38 | -10.4 | - | - | - |
| EBIT 1 | -17.4 | -20.7 | -13.24 | -9.159 | -7.108 | -9.948 |
| Operating Margin | -80.51% | -93.78% | -72.59% | -49.92% | -40.5% | -77.73% |
| Earnings before Tax (EBT) 1 | -21.39 | -24.37 | -17.14 | -11.71 | -35.7 | -3.729 |
| Net income 1 | -21.39 | -24.37 | -17.14 | -11.71 | -35.7 | -3.729 |
| Net margin | -98.97% | -110.43% | -93.97% | -63.83% | -203.4% | -29.14% |
| EPS 2 | -2.000 | -20.00 | -1.200 | -0.8000 | -2.400 | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/30/21 | 3/17/22 | 6/23/22 | 11/7/22 | 11/29/22 | 4/28/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 57.1 | 49.8 | 103 | - |
| Net Cash position 1 | 53.2 | 44.1 | - | - | - | 4.4 |
| Leverage (Debt/EBITDA) | - | - | -1.029 x | -0.7677 x | -2.809 x | - |
| Free Cash Flow 1 | -21.5 | -25.5 | -62.3 | -38.3 | -52.4 | -18.2 |
| ROE (net income / shareholders' equity) | -80.7% | -76.1% | -206% | -860% | 363% | -103% |
| ROA (Net income/ Total Assets) | -41.1% | -39.6% | -30.9% | -25% | -15.7% | -15.7% |
| Assets 1 | 94.56 | 106.9 | 246.5 | 391.3 | 455.1 | -152.2 |
| Book Value Per Share 2 | 72.20 | 68.00 | 14.40 | 6.740 | -20.80 | 0.1100 |
| Cash Flow per Share 2 | 40.90 | 32.90 | 30.50 | 22.40 | 8.570 | 0.2800 |
| Capex 1 | 0.02 | 0.17 | 0.41 | 0.12 | 0.2 | 0.01 |
| Capex / Sales | 0.28% | 2.67% | 0.63% | 0.13% | 0.32% | 0.17% |
| Announcement Date | 2/26/19 | 3/4/20 | 3/18/21 | 3/17/22 | 4/28/23 | 4/8/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -70.68% | 13.64M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- RDHL Stock
- Financials RedHill Biopharma Ltd.
